# ImmunityBio ImmunityBio is an Asset Manager based in Culver City, United States. ## Overview - **Organization type:** Asset Manager - **Headquarters:** Culver City, United States - **Region:** North America - **Address:** Culver City, CA, United States - **Founded:** 2014 - **Assets under management:** Undisclosed - **Website:** immunitybio.com - **LinkedIn:** https://www.linkedin.com/company/immunitybio ## Regulatory record - **Reports private funds:** No ## About ImmunityBio was formed in 2014 by Patrick Soon-Shiong, the surgeon-entrepreneur who previously built and sold Abraxis BioScience, maker of the cancer drug Abraxane, to Celgene in 2010. The firm's founding thesis was that the first wave of immuno-oncology drugs — PD-1 and PD-L1 inhibitors — helps only a minority of patients, and that a durable response requires coordinating both the innate and adaptive arms of the immune system. Soon-Shiong seeded the company with his own capital and later took it public via a reverse merger in 2020, keeping majority voting control. ImmunityBio's lead clinical programs are built around Anktiva (N-803), an IL-15 superagonist complex designed to stimulate natural killer and CD8+ T-cells. The drug is in late-stage trials for bladder cancer, non-small cell lung cancer, and pancreatic cancer. In April 2024, the FDA approved Anktiva plus BCG for BCG-unresponsive non-muscle invasive bladder cancer — the company's first commercial product. The firm also operates a portfolio of cell-therapy platforms, including CAR-NK and PD-L1-targeting CAR-T constructs, and runs a manufacturing network in California with facilities capable of cell therapy and large-molecule production. Beyond oncology, ImmunityBio has pursued infectious-disease applications, including a COVID-19 vaccine candidate that received a thumbs-down from the FDA's advisory committee in 2021. The firm is headquartered in Culver City, California, and employs a vertically integrated model where clinical development, manufacturing, and a proprietary delivery device are kept in-house. In April 2024, the FDA approval of Anktiva triggered a $320 million equity raise to fund the commercial launch, drawing on Soon-Shiong's relationship network and existing institutional holders (per public filings, April 2024). Adjacent commercial infrastructure includes a specialty pharmacy partnership with a national provider to manage patient access for the bladder cancer indication. ImmunityBio's distinguishing architecture is its public-market vehicle controlled by a founder who functions as both chief scientific officer and majority shareholder, blurring the line between a single-family biotech bet and an institutional-stage company. Where most family offices limit their life-sciences exposure to fund commitments or passive co-investments, Soon-Shiong has concentrated roughly a decade of effort and over $2 billion in deployed capital into a single pipeline — a governance structure that concentrates both scientific risk and boardroom authority under one person. ## Sectors - Biotechnology - Immunotherapy ## People - Patrick Soon-Shiong — Executive Chairman & Global Chief Scientific and Medical Officer ## Questions ### Who runs the science decisions at ImmunityBio? Patrick Soon-Shiong serves as both Executive Chairman and Global Chief Scientific and Medical Officer, a dual role that places scientific strategy and clinical direction squarely with the founder. The company's pipeline prioritization and clinical-trial design were led by Dr. Soon-Shiong and his internal R&D team through the first FDA approval in 2024. ### Where does the underlying capital for ImmunityBio come from? Much of the initial and ongoing capital has come from Patrick Soon-Shiong himself, following the $2.9 billion sale of Abraxis BioScience to Celgene in 2010. He has used his personal fortune to fund the company's clinical trials and manufacturing buildout, supplemented by public-market equity raises after the 2020 reverse merger. ### What is ImmunityBio's lead drug candidate? Anktiva (N-803) is an IL-15 superagonist complex intended to boost natural killer and CD8+ T-cell activity. It received its first FDA approval in April 2024 for BCG-unresponsive non-muscle invasive bladder cancer when combined with BCG, and the company is pursuing additional indications in lung and pancreatic cancers. ### Does ImmunityBio have its own manufacturing capability? Yes. The company operates a manufacturing campus in Southern California with capacity to produce cell therapies and large-molecule biologics in-house, a vertical-integration strategy intended to control cost and supply chain for its proprietary products. ### How does ImmunityBio's approach differ from standard checkpoint inhibitors? Checkpoint inhibitors like PD-1 and PD-L1 drugs try to release the brakes on T-cells. ImmunityBio's thesis is that a durable immune response requires activating both innate and adaptive immunity simultaneously, which their IL-15 superagonist platform and cell-therapy candidates are designed to do. ## Related profiles - [Noble Corp plc](https://altss.com/profile/noble-corp-plc) - [Acuity Inc.](https://altss.com/profile/acuity-inc-de) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/immunitybio-inc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology